In summary, NKT cells seem to be decreased by activation of KCs through enhanced production of IL-12 at an early stage of NAFLD, whereas those are increased by upregulation of CD1d expression through increased production of adipokines or gut-derived microbiota at an advanced stage of NAFLD in humans. This evidence concerns the gene CD1D and metabolic dysfunction-associated steatotic liver disease.